Background The combination of ivosidenib — an inhibitor of mutant isocitrate dehydrogenase
1 (IDH1) — and azacitidine showed encouraging clinical activity in a phase 1b trial …

… This is significant because we were unable to assess EPZ004777’s ability to inhibit these
HMTs directly due a lack of robust biochemical assays. These data are consistent with …

Background Pregnant women with type 1 diabetes are a high-risk population who are
recommended to strive for optimal glucose control, but neonatal outcomes attributed to maternal …

… As shown in Figure 3B, EPZ-5676 treatment led to an increase in the percentage of cells in
the G0/G1 phase of the cell cycle and a decrease in the percentage of cells in S-phase cells …

Pinometostat (EPZ-5676) is a first-in-class small-molecule inhibitor of the histone methyltransferase
disrupter of telomeric silencing 1-like (DOT1L). In this phase 1 study, pinometostat …

Among 377,561 female Medicare beneficiaries who sustained a fracture, 10% had another
fracture within 1 year, 18% within 2 years, and 31% within 5 years. Timely management to …

PURPOSE Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1)
enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML). …

Background Although metformin is increasingly being used in women with type 2 diabetes
during pregnancy, little data exist on the benefits and harms of metformin use on pregnancy …

As teachers of higher education, we expect students to enter college with some understanding
of what it means to be an effective learner and the ability to apply effective learning …

… All mice used in this study were housed in the Animal Research Facility at Children’s Hospital
Boston. Animal experiments and protocols were approved by the Internal Animal Care and …